MASI vs. ITGR, TMDX, LIVN, CNMD, INMD, CYTK, RVMD, STVN, EXEL, and XRAY
Should you be buying Masimo stock or one of its competitors? The main competitors of Masimo include Integer (ITGR), TransMedics Group (TMDX), LivaNova (LIVN), CONMED (CNMD), InMode (INMD), Cytokinetics (CYTK), Revolution Medicines (RVMD), Stevanato Group (STVN), Exelixis (EXEL), and DENTSPLY SIRONA (XRAY). These companies are all part of the "medical" sector.
Masimo (NASDAQ:MASI) and Integer (NYSE:ITGR) are both mid-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, community ranking, profitability, valuation and dividends.
In the previous week, Integer had 2 more articles in the media than Masimo. MarketBeat recorded 18 mentions for Integer and 16 mentions for Masimo. Integer's average media sentiment score of 0.65 beat Masimo's score of 0.41 indicating that Integer is being referred to more favorably in the news media.
Masimo has a beta of 0.99, meaning that its share price is 1% less volatile than the S&P 500. Comparatively, Integer has a beta of 1.12, meaning that its share price is 12% more volatile than the S&P 500.
86.0% of Masimo shares are owned by institutional investors. Comparatively, 99.3% of Integer shares are owned by institutional investors. 9.7% of Masimo shares are owned by insiders. Comparatively, 2.0% of Integer shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Masimo presently has a consensus target price of $138.71, suggesting a potential upside of 11.78%. Integer has a consensus target price of $128.67, suggesting a potential upside of 6.41%. Given Masimo's higher possible upside, equities research analysts clearly believe Masimo is more favorable than Integer.
Integer has lower revenue, but higher earnings than Masimo. Integer is trading at a lower price-to-earnings ratio than Masimo, indicating that it is currently the more affordable of the two stocks.
Masimo received 76 more outperform votes than Integer when rated by MarketBeat users. Likewise, 63.84% of users gave Masimo an outperform vote while only 63.51% of users gave Integer an outperform vote.
Integer has a net margin of 6.01% compared to Masimo's net margin of 4.01%. Masimo's return on equity of 13.26% beat Integer's return on equity.
Summary
Masimo and Integer tied by winning 9 of the 18 factors compared between the two stocks.
Get Masimo News Delivered to You Automatically
Sign up to receive the latest news and ratings for MASI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MASI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Related Companies and Tools